(CercleFinance.com) – Guerbet announces that it has reached an agreement today with Merative terminating their collaboration signed in July 2018.
This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancer.
According to Guerbet, this agreement now gives it all the strategic latitude it needs to continue the work in progress and to plan the marketing of the solutions.
In particular, it allows Guerbet to recover all the assets developed by the partnership, such as source codes and algorithms
as well as their intellectual property.
Guerbet also specifies that the quality of the presentation of the work of its Artificial Intelligence research team recently convinced the jury of the BPI France 2030 program and enabled it to obtain funding from 1ME for its project in the early detection of cancer. of the pancreas, as recently announced.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
